CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183–91/HLA-A *0201 exhibit potent activity against HBV-HCC

CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183–91/HLA-A *0201 exhibit potent activity against HBV-HCC

CAR-T cell therapy demonstrates significant efficacy in hematologic malignancies, with target selection critically determining therapeutic outcomes. However, the available tumor surface antigens are limited, especially in the treatment of solid tumors. A potential solution to overcome this limitatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Fengling Wang, Jiaqian Li, Yong Huang, Feiyang Yan, Haozhan Gao, Weilin Zhou, Xinyu Gu, Dan Li, Yalan Zhang, Jing Li, Yuening Yang, Jiangping Yang, Mengxi Zhang, Jinrong Yang, Shimao Qi, Wei Wang
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Chimeric antigen receptor
HBV-HCC
MHC
TCR-like antibody
Env183-191 epitope
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2546404
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items